Madrigal Pharmaceuticals’ cover photo
Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Pharmaceutical Manufacturing

Conshohocken, Pennsylvania 65,931 followers

Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.

About us

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Learn more about us at www.madrigalpharma.com

Website
https://www.madrigalpharma.com/
Industry
Pharmaceutical Manufacturing
Company size
501-1,000 employees
Headquarters
Conshohocken, Pennsylvania
Type
Public Company
Founded
2016
Specialties
Liver Disease, NASH, Metabolic Disease, and MASH

Locations

  • Primary

    200 Barr-Harbor Dr

    Suite 200

    Conshohocken, Pennsylvania 19428, US

    Get directions

Employees at Madrigal Pharmaceuticals

Updates

Similar pages

Browse jobs

Funding

Madrigal Pharmaceuticals 9 total rounds

Last Round

Post IPO debt

US$ 350.0M

Investors

Blue Owl
See more info on crunchbase